Mirum Pharmaceuticals, Inc.
MIRM
Clasificación en acciones
#3217
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Precio por acción
$85.12
Capitalización bursátil
$5.53B
Cambio (1 día)
3.50%
Cambio (1 año)
16.55%
País
US
Comercio Mirum Pharmaceuticals, Inc. (MIRM)
Categoría
Healthcare
Ratio P/B de Mirum Pharmaceuticals, Inc. (MIRM)
Ratio P/B al October 2026 TTM: -486.22
Según los informes financieros más recientes y el precio de las acciones de Mirum Pharmaceuticals, Inc., el ratio P/B actual (TTM) es -486.22. Al final de 2023, el ratio P/B era 4.85.
Historial del ratio P/B de Mirum Pharmaceuticals, Inc. desde 2018 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | -486.22 | -5,682.34% |
| 2024 | 8.71 | 79.44% |
| 2023 | 4.85 | -388.93% |
| 2022 | -1.68 | -141.75% |
| 2021 | 4.02 | -258.02% |
| 2020 | -2.55 | -68.43% |
| 2019 | -8.06 | -72.59% |
| 2018 | -29.42 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | -101.29% |
US
|
|
| 13.2547 | -102.73% |
US
|
|
| 4.208 | -100.87% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -101.27% |
NL
|
